[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"normal\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:normal":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,68,91],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100601358","to-assess-skin-safety-of-test-products-by-patch-test-on-adult-healthy-human-subjects-100601358",false,"NCT07109453","To Assess Skin Safety of Test Product(s) by Patch Test on Adult Healthy Human Subjects","Dermatological Safety Assessment of Test Products Using Primary Irritation Patch Test (PIPT) in Healthy Adult Human Subjects","Inclusion Criteria\n\n* Age: 18-65 years (both inclusive) at the time of consent.\n* Sex: Males and non-pregnant\u002Fnon-lactating females (preferably equal number of males and females).\n* Subject with normal Fitzpatrick skin type III to V (Human skin colour determination scale).\n* Females of childbearing potential must have a self-reported negative pregnancy test.\n* Subject who do not have any previous\n* history of adverse skin conditions and are not under any medication likely to interfere with the results.\n* Subject is in good general health as determined by\n* the Investigator on the basis of medical history.\n* Subjects is willing to maintain the test patches in designated positions for 24 Hours.\n* Subject is willing and able to follow the study directions, to participate in the study, returning for all specified visits.\n* Subject must be able to understand and provide written informed consent to participate in the study.\n* Subject is willing to refrain from vigorous physical exercise during the study period and follow all the instruction given.\n* For Sensitive Skin Condition Only:\n* Subject scoring greater than 30 for Section 2 - Sensitive v\u002Fs Resistant skin in modified Dr Baumann's\\* skin type questionnaire.\n* Subject with sensitive skin as confirmed by Lactic Acid Stinging Test.\n\nExclusion Criteria:\n\n* Subject having skin irritation, blemishes, excessive hair, moles, pigmentation, pimples, marks (e.g. tattoos (within the previous 3 months), scars, sunburn), open wounds, cuts, abrasions, irritation symptoms or any dermatological condition on the test site(s) i.e. back that can interfere with the reading.\n* Medication which may affect skin response and\u002For past medical history.\n* Subject having history of diabetes\n* Subject have history of mastectomy for cancer involving removal of lymph nodes within the past year, or treatment of any type of cancer within the last 6 months.\n* Subject suffering from any active clinically significant skin diseases which may contraindicate.\n* Subject having history of any skin diseases including eczema, atopic dermatitis or active cancer.\n* Participation in any patch test for irritation or sensitization within the last four weeks.\n* Subject having history of asthma or COPD (Chronic obstructive pulmonary disease).\n* Use of any:\n* Prescribed or over-the-counter (OTC) anti-inflammatory drug within five (5) days prior to application.\n* Antihistamine medication or immunosuppressive drugs within seven (7) days prior to first patch application. iii. Systemic or topical corticosteroids at patch site within four (4) weeks of test product application (steroidal nose drops and\u002For eye drops are permitted)\n* Topical drugs used at application site.\n* Subject with Self-reported Immunological disorders such as HIV positive, AIDS and\u002For systemic lupus erythematous.\n* Individual who has a medical condition or is taking or has taken a medication which, in the Investigator's judgment, makes the subject ineligible or places the subject at undue risk.\n* Subject with known allergy or sensitization to medical adhesives, bandages.\n* Participation in other patch study simultaneously",true,"ALL","18 Years","65 Years",{"count":21,"type":22},26,"ESTIMATED","INTERVENTIONAL",[25],"NA","To Check Dermatological Safety of Test Products by 24 Hours Patch Testing",[28,29],"Normal","Sensitive Skin","NOT_YET_RECRUITING","2025-08-07",{"date":33,"type":34},"2025-08-08","ACTUAL",{"date":36,"type":22},"2025-08-25",{"date":38,"type":22},"2025-09",{"name":40,"class":41},"NovoBliss Research Pvt Ltd","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":49,"targetDuration":51,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100597181","retinal-octa-for-microvascular-dysfunction-evaluation-and-outcome-prediction-in-minoca-patients-100597181","NCT07055152","Retinal OCTA for Microvascular Dysfunction Evaluation and Outcome Prediction in MINOCA Patients","REVEAL","Inclusion Criteria:\n\n* Age: Patients aged \\> 18.\n\nDiagnosis:\n\nMINOCA Group: Patients diagnosed with Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA) confirmed by coronary angiography.\n\nACS Group: Patients with Acute Coronary Syndrome (ACS) with significant coronary artery stenosis which are matched with MINOCA patients for gender, age, LVEF at admission and chronic kidney disease stage.\n\nHealthy Controls: Age and gender-matched healthy individuals with no history of cardiovascular disease.\n\nConsent: Written informed consent obtained from all participants. Feasibility: Ability to undergo OCTA and other required imaging procedures.\n\nExclusion Criteria:\n\n* Ocular Conditions: Any significant ocular disease (e.g., glaucoma, diabetic retinopathy, macular degeneration) that could interfere with OCTA imaging quality.\n\nSevere Comorbidities: Presence of severe systemic diseases, such as advanced renal failure, active cancer, or severe liver disease, which might impact study participation.\n\nCoronary Artery Disease or Myocarditis: For the MINOCA group, patients with coronary artery stenosis \\> 50% or functionally significant (FFR \\\u003C0.8) or patients with Myocarditis detected through CMR will be excluded Pregnancy: Pregnant or breastfeeding women. Inability to Comply: Patients unable or unwilling to comply with study procedures, including follow-up visits.",{"count":50,"type":22},90,"24 Months","OBSERVATIONAL","The aim of this study is to evaluate microvascular dysfunction through OCTA in MINOCA patients. In order to better understand the condition, OCTA will also be performed in two matched patient groups: healthy controls and ACS patients. The study will compare the retinal microvascular parameters across these groups to determine differences in microvascular function in MINOCA patients. Additionally, in the MINOCA subgroup, the study will further evaluate the differences in microvascular dysfunction within specific subsets of patients (e.g., Takotsubo, vasospastic angina, microvascular angina, patients with evidence of plaque erosion) to understand the variability and potential mechanisms underlying each subgroup of MINOCA.",[55,56,28],"MINOCA","STEMI","RECRUITING","2025-07-03",{"date":60,"type":34},"2025-07-08",{"date":62,"type":34},"2025-01-01",{"date":64,"type":22},"2027-01-01",{"name":66,"class":41},"University of Pisa",1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":16,"sex":17,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":4},"100570249","investigation-of-the-possibility-of-determining-cerebrovascular-disease-based-on-hemodynamic-information-of-localized-brain-regions-100570249","NCT06704789","Investigation of the Possibility of Determining Cerebrovascular Disease Based on Hemodynamic Information of Localized Brain Regions","Inclusion Criteria :\n\n1. For Hemorrhagic Stroke Patients :\n\n   * Adults aged between 19 and 80 years.\n   * Diagnosed with hemorrhagic stroke through clinical observation and neuroimaging.\n   * First-time hemorrhagic stroke patients.\n   * Hemorrhagic stroke onset between 2 weeks and 12 months prior to screening.\n   * Hemorrhagic lesion located in the cortex or subcortex.\n   * Not taking medications that could affect brain hemodynamics, such as - antihypertensives, anticoagulants, antiplatelets, or antidepressants.\n   * Able to read and understand the informed consent form and participate in questionnaires with sufficient language proficiency.\n   * Voluntarily agree to participate in the study and provide written consent, with the ability to complete the study duration.\n2. For Ischemic Stroke Patients :\n\n   * Adults aged between 19 and 80 years.\n   * Diagnosed with ischemic stroke through clinical observation and neuroimaging.\n   * First-time ischemic stroke patients.\n   * Ischemic stroke onset between 2 weeks and 12 months prior to screening.\n   * Ischemic lesion located in the cortex or subcortex.\n   * Not taking medications that could affect brain hemodynamics, such as antihypertensives, anticoagulants, antiplatelets, or antidepressants.\n   * Able to read and understand the informed consent form and participate in questionnaires with sufficient language proficiency.\n   * Voluntarily agree to participate in the study and provide written consent, with the ability to complete the study duration.\n3. For Healthy Adults :\n\n   * Adults aged between 19 and 80 years.\n   * No history of stroke or transient ischemic attack (TIA).\n   * No stroke risk factors such as hypertension, diabetes, or hyperlipidemia.\n   * No chronic diseases (e.g., cardiovascular disease, chronic kidney disease, chronic lung disease).\n   * No psychiatric conditions (e.g., depression, schizophrenia).\n   * Not taking medications that could affect brain hemodynamics, such as antihypertensives, anticoagulants, antiplatelets, or antidepressants.\n   * Able to read and understand the informed consent form and participate in questionnaires with sufficient language proficiency.\n   * Voluntarily agree to participate in the study and provide written consent, with the ability to complete the study duration.\n\nExclusion Criteria :\n\n* History of head trauma in the past 6 months.\n* Ongoing severe chronic diseases (e.g., heart failure, chronic kidney disease, chronic lung disease).\n* Severe psychiatric disorders such as schizophrenia, major depression, or bipolar disorder.\n* Use of medications that could influence brain hemodynamics (e.g., antihypertensives, anticoagulants, antiplatelets, or antidepressants).\n* Participation in a study and use of experimental drugs within the past 30 days.\n* Pregnant or breastfeeding women.\n* Major surgery in the past 6 months.\n* Acute infections or inflammatory diseases.\n* Cognitive impairment or dementia.\n* Neurological disorders.\n* Inability to understand the study procedures or unwillingness to provide voluntary consent.\n* Any other clinical concerns deemed inappropriate for participation by the principal investigator or study team.","19 Years","80 Years",{"count":50,"type":22},"The purpose of this study is to compare hemodynamic information from localized brain regions between stroke patients and healthy adults using brain activity data (fNIRS and EEG) and to assess the accuracy of early stroke diagnosis and classification predictions.",[79,80,81,28],"EEG","FNIRS","Stroke","2024-11-21",{"date":84,"type":34},"2024-11-26",{"date":86,"type":22},"2024-12-01",{"date":88,"type":22},"2025-12-31",{"name":90,"class":41},"Pusan National University Yangsan Hospital",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":16,"sex":17,"minAge":74,"maxAge":75,"enrollmentInfo":97,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":105,"leadSponsor":106,"locationsCount":4},"100570012","exploratory-study-on-artifact-denoising-of-cerebral-blood-flow-and-eeg-data-in-ambulance-settings-100570012","NCT06701708","Exploratory Study on Artifact Denoising of Cerebral Blood Flow and EEG Data in Ambulance Settings","Inclusion Criteria:\n\n* Healthy adults aged 19 to 80 years.\n* Individuals without chronic diseases (e.g., Stage 2 hypertension, cardiovascular disease, chronic kidney disease, chronic pulmonary disease, etc.).\n* Individuals without mental health disorders (e.g., depression, schizophrenia, etc.).\n* Individuals not taking medications that could affect cerebral hemodynamics, such as antihypertensives, anticoagulants, antiplatelets, antidepressants, etc.\n\nIndividuals who can read and understand the participant information and consent form and have sufficient language ability to respond to questionnaires.\n\n\\- Individuals who voluntarily decide to participate in the clinical study, provide written consent on the participant consent form, and are able to participate throughout the entire duration of the clinical study.\n\nExclusion Criteria:\n\n* Individuals who have experienced head trauma in the past 6 months.\n* Individuals with ongoing severe chronic diseases (e.g., heart failure, chronic kidney disease, chronic pulmonary disease, etc.).\n* Individuals with severe mental health disorders such as schizophrenia, severe depression, bipolar disorder, etc.\n* Individuals currently taking medications that may affect the study (e.g., antihypertensives, anticoagulants, antiplatelets, antidepressants, etc.).\n* Individuals who have participated in a clinical trial and taken experimental drugs within the past 30 days.\n* Women who are pregnant or breastfeeding.\n* Individuals who have undergone major surgery in the past 6 months.\n* Individuals with acute infections or inflammatory diseases.\n* Individuals with cognitive impairment or dementia.\n* Individuals with neurological disorders.\n* Individuals who lack understanding of the study procedures or who have not voluntarily consented to participate.\n* Individuals with clinically significant findings that the study principal investigator or responsible medical personnel determines to be inappropriate for participation in this study.",{"count":98,"type":22},20,"The purpose is to assess the extent of digital noise occurring during the measurement of cerebral blood flow and EEG in healthy adults within an ambulance setting and to explore the possibility of identifying and correcting abnormal patterns.",[28,79,80],"2024-11-20",{"date":103,"type":34},"2024-11-22",{"date":86,"type":22},{"date":88,"type":22},{"name":90,"class":41}]